Du är här

2014-04-22

Orion Oyj: Publishing of Orion Corporation's Interim Report for January-March 2014 on 29 April 2014

ORION CORPORATION STOCK EXCHANGE RELEASE 22 APRIL 2014 at 10:45 A.M.
EEST

Publishing of Orion Corporation's Interim Report for January-March 2014 on 29
April 2014

Orion will publish its Interim Report for January-March 2014 on Tuesday, 29
April 2014 approximately at 12:00 Finnish time (EEST). The release and
related presentation material in Finnish and in English will be available on
the Group's homepage atwww.orion.fi/en/investorspromptly after the
publishing.

News conference for analysts and media on Tuesday 29 April 2014 at 13:30 EESTA news conference for analysts and media will be held on Tuesday 29 April 2014
at 13:30 EEST at Hotel Kämp,
address Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will
give a brief presentation in English on the financial review.

Live webcast and conference callThe event can be followed live as a webcast accessible
athttp://qsb.webcast.fi/o/orion/orion_2014_0429_q1.

Questions can be asked also through conference call lines after the result
presentation. The conference call ID is 943080 and the phone numbers to
participate the conference are:

when calling from the United States +1 334 323 6201
when calling from other countries +44 (0)20 7162 0025

News conference recordingsA recording of the event in English and a recording of the presentation by the
President and CEO in Finnish will be available on the Orion website later the
same day.

Silent periodThe silent period preceding the publication is ongoing and continues until the
disclosure.

Orion Corporation

---------------------------------
|Timo Lappalainen Jari Karlson |
|President and CEO |
| CFO |
---------------------------------
Publisher:
Orion Corporation
www.orion.fi/en
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical
ingredients and diagnostic tests. The company is continuously developing new
drugs and treatment methods. Pharmaceutical R&D focuses on central nervous
system drugs, oncology and critical care drugs, and Easyhaler® pulmonary
drugs.

Orion's net sales in 2013 amounted to EUR 1,007 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX
Helsinki.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire

HUG#1778560

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.